Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Warm autoimmune hemolytic anemia is the most common form of autoimmune hemolytic anemia defined by the presence of warm autoantibodies against red blood cells (autoantibodies that are active at temperatures between 37-40B0C).
Biomarker and diagnostic research for autoimmune hemolytic anemia, warm type has been reported in the published literature.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
14 clinical trials registered, 5 recruiting. Interventions under study include drug therapy, biologic therapy, and other interventions. Pipeline includes 3 PHASE3, 4 PHASE2, 3 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07083960](https://clinicaltrials.gov/study/NCT07083960) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:45 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about autoimmune hemolytic anemia, warm type
OM336 in Autoimmune Cytopenias |
PHASE1 |
Lakefront Biotherapeutics West LLC |
RECRUITING |
[NCT07019038](https://clinicaltrials.gov/study/NCT07019038) | National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia | — | Institute of Hematology & Blood Diseases Hospital, China | RECRUITING |
[NCT05925023](https://clinicaltrials.gov/study/NCT05925023) | Sirolimus in the Treatment of Refractory/Relapsed wAIHA | NA | Peking Union Medical College Hospital | RECRUITING |
[NCT07039422](https://clinicaltrials.gov/study/NCT07039422) | Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab | PHASE2 | Novartis Pharmaceuticals | RECRUITING |
[NCT07549698](https://clinicaltrials.gov/study/NCT07549698) | Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease | PHASE1 | CRISPR Therapeutics AG | RECRUITING |
117 publications have been identified in PubMed for autoimmune hemolytic anemia, warm type. Research spans Case Report / Case Series (45%), Review / Meta-Analysis (23%), and Epidemiology / Natural History (10%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 52 | 45% |
Research summaries | 26 | 23% |
Disease patterns and progression | 12 | 10% |
Other research | 7 | 6% |
Clinical study results | 7 | 6% |
Laboratory research | 5 | 4% |
Testing and diagnosis research | 3 | 3% |
New treatment approaches | 3 | 3% |
Hale I (2026). [PMID: 41824628](https://pubmed.ncbi.nlm.nih.gov/41824628/). *Acta Haematol*. [Case Report / Case Series]
Ferreira Sacramento G (2026). [PMID: 41625053](https://pubmed.ncbi.nlm.nih.gov/41625053/). *Cureus*. [Case Report / Case Series]
Tripathi AK (2026). [PMID: 39163433](https://pubmed.ncbi.nlm.nih.gov/39163433/). *Unknown Journal*. [Diagnostic / Biomarker]
S M (2026). [PMID: 41694896](https://pubmed.ncbi.nlm.nih.gov/41694896/). *Cureus*. [Case Report / Case Series]
Ma C (2026). [PMID: 41575164](https://pubmed.ncbi.nlm.nih.gov/41575164/). *J Int Med Res*. [Case Report / Case Series]
Iwamoto Y (2026). [PMID: 41951410](https://pubmed.ncbi.nlm.nih.gov/41951410/). *Intern Med*. [Case Report / Case Series]
Michel M (2026). [PMID: 42067402](https://pubmed.ncbi.nlm.nih.gov/42067402/). *Rev Med Interne*. [Review / Meta-Analysis]
Fattizzo B (2026). [PMID: 41061187](https://pubmed.ncbi.nlm.nih.gov/41061187/). *Blood Adv*. [Gene Therapy / Novel Therapeutics]
Jabbari-Zadeh F (2026). [PMID: 41613625](https://pubmed.ncbi.nlm.nih.gov/41613625/). *Ther Adv Hematol*. [Case Report / Case Series]
Anya O (2026). [PMID: 42131782](https://pubmed.ncbi.nlm.nih.gov/42131782/). *Case Rep Hematol*. [Case Report / Case Series]
AI-curated news mentioning autoimmune hemolytic anemia, warm type
Updated Sep 1, 2026
IMAVVY has been approved as the first targeted therapy for warm autoimmune hemolytic anemia (wAIHA), effectively reducing pathogenic IgG while preserving B-cell function. This marks a significant advancement in treatment options for patients suffering from this condition.
The phase 2/3 ENERGY study demonstrates promising results for nipocalimab in treating warm autoimmune hemolytic anemia. This randomized, double-blind trial highlights the potential of nipocalimab as a therapeutic option for this condition.
A new study reports on the use of anifrolumab to target type I interferon in patients with lupus autoimmune hemolytic anemia. This research could pave the way for novel therapeutic strategies in managing this condition.
A new French protocol outlines the diagnosis and management strategies for autoimmune hemolytic anemia in adults. This protocol aims to standardize care and improve patient outcomes in this rare condition.
A 47-year-old woman in Germany was cured of three severe autoimmune diseases—autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome—using CAR-T cell therapy, traditionally used for blood cancers. This breakthrough highlights the potential of CAR-T therapy beyond oncology, offering new hope for patients with refractory autoimmune conditions.